(HWKN) Hawkins - Overview
Stock: Chemicals, Ingredients, Water-Treatment, Industrial-Blends, Nutraceuticals
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.55% |
| Yield on Cost 5y | 3.26% |
| Yield CAGR 5y | 4.19% |
| Payout Consistency | 98.0% |
| Payout Ratio | 18.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 39.5% |
| Relative Tail Risk | -9.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.38 |
| Alpha | 1.91 |
| Character TTM | |
|---|---|
| Beta | 0.792 |
| Beta Downside | 0.320 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.79% |
| CAGR/Max DD | 1.39 |
Description: HWKN Hawkins January 12, 2026
Hawkins, Inc. (NASDAQ:HWKN) is a U.S.–based provider of water-treatment chemicals, industrial specialty chemicals, and health-nutrition ingredients. The business is organized into three segments: (1) Water Treatment, which supplies chemicals, equipment, and services for potable, municipal, industrial, agricultural, and swimming-pool water; (2) Industrial, which manufactures and distributes bulk and blended chemicals-including sodium hypochlorite, liquid caustic soda, and phosphoric acid-for sectors such as agriculture, electronics, energy, and pharmaceuticals; and (3) Health & Nutrition, which distributes minerals, vitamins, amino acids, botanicals, and other functional ingredients to nutraceutical and personal-care manufacturers.
In FY 2023 Hawkins reported revenue of approximately $1.1 billion, a 5 % year-over-year increase driven primarily by higher demand for water-treatment solutions in municipalities coping with aging infrastructure. Adjusted EBITDA margin hovered around 12 %, reflecting modest pricing power but also exposure to raw-material cost volatility (e.g., chlorine and caustic soda). The global water-treatment market is projected to grow at a 5-6 % CAGR through 2029, while specialty chemicals for health-nutrition benefit from secular trends in functional foods and aging populations, both of which support demand growth for Hawkins’ ingredient portfolio.
If you want a data-rich, quantitative deep-dive on HWKN’s valuation and risk profile, the ValueRay platform offers a concise analyst dashboard that can help you benchmark the company against peers.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 82.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -2.36 > 1.0 |
| NWC/Revenue: 12.33% < 20% (prev 13.24%; Δ -0.92% < -1%) |
| CFO/TA 0.14 > 3% & CFO 137.4m > Net Income 82.4m |
| Net Debt (270.1m) to EBITDA (173.4m): 1.56 < 3 |
| Current Ratio: 2.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.8m) vs 12m ago -0.15% < -2% |
| Gross Margin: 22.86% > 18% (prev 0.23%; Δ 2263 % > 0.5%) |
| Asset Turnover: 126.3% > 50% (prev 134.6%; Δ -8.35% > 0%) |
| Interest Coverage Ratio: 10.27 > 6 (EBITDA TTM 173.4m / Interest Expense TTM 12.1m) |
Altman Z'' 4.62
| A: 0.13 (Total Current Assets 228.2m - Total Current Liabilities 97.2m) / Total Assets 976.5m |
| B: 0.50 (Retained Earnings 488.7m / Total Assets 976.5m) |
| C: 0.15 (EBIT TTM 123.9m / Avg Total Assets 841.9m) |
| D: 1.07 (Book Value of Equity 489.8m / Total Liabilities 457.6m) |
| Altman-Z'' Score: 4.62 = AA |
Beneish M -2.81
| DSRI: 0.99 (Receivables 123.7m/111.5m, Revenue 1.06b/952.1m) |
| GMI: 1.01 (GM 22.86% / 22.98%) |
| AQI: 1.31 (AQ_t 0.49 / AQ_t-1 0.37) |
| SGI: 1.12 (Revenue 1.06b / 952.1m) |
| TATA: -0.06 (NI 82.4m - CFO 137.4m) / TA 976.5m) |
| Beneish M-Score: -2.81 (Cap -4..+1) = A |
What is the price of HWKN shares?
Over the past week, the price has changed by -15.92%, over one month by -13.85%, over three months by +0.80% and over the past year by +12.09%.
Is HWKN a buy, sell or hold?
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HWKN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 188 | 45.4% |
| Analysts Target Price | 188 | 45.4% |
| ValueRay Target Price | 180.1 | 39.3% |
HWKN Fundamental Data Overview February 03, 2026
P/E Forward = 26.9542
P/S = 2.4577
P/B = 5.2466
P/EG = 2.2615
Revenue TTM = 1.06b USD
EBIT TTM = 123.9m USD
EBITDA TTM = 173.4m USD
Long Term Debt = 253.4m USD (from longTermDebt, last quarter)
Short Term Debt = 9.81m USD (from shortTermDebt, last quarter)
Debt = 278.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 270.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.88b USD (2.61b + Debt 278.3m - CCE 8.21m)
Interest Coverage Ratio = 10.27 (Ebit TTM 123.9m / Interest Expense TTM 12.1m)
EV/FCF = 32.88x (Enterprise Value 2.88b / FCF TTM 87.7m)
FCF Yield = 3.04% (FCF TTM 87.7m / Enterprise Value 2.88b)
FCF Margin = 8.25% (FCF TTM 87.7m / Revenue TTM 1.06b)
Net Margin = 7.75% (Net Income TTM 82.4m / Revenue TTM 1.06b)
Gross Margin = 22.86% ((Revenue TTM 1.06b - Cost of Revenue TTM 820.0m) / Revenue TTM)
Gross Margin QoQ = 20.82% (prev 24.12%)
Tobins Q-Ratio = 2.95 (Enterprise Value 2.88b / Total Assets 976.5m)
Interest Expense / Debt = 1.23% (Interest Expense 3.43m / Debt 278.3m)
Taxrate = 26.91% (5.27m / 19.6m)
NOPAT = 90.6m (EBIT 123.9m * (1 - 26.91%))
Current Ratio = 2.35 (Total Current Assets 228.2m / Total Current Liabilities 97.2m)
Debt / Equity = 0.54 (Debt 278.3m / totalStockholderEquity, last quarter 518.9m)
Debt / EBITDA = 1.56 (Net Debt 270.1m / EBITDA 173.4m)
Debt / FCF = 3.08 (Net Debt 270.1m / FCF TTM 87.7m)
Total Stockholder Equity = 492.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.79% (Net Income 82.4m / Total Assets 976.5m)
RoE = 16.73% (Net Income TTM 82.4m / Total Stockholder Equity 492.7m)
RoCE = 16.61% (EBIT 123.9m / Capital Employed (Equity 492.7m + L.T.Debt 253.4m))
RoIC = 12.24% (NOPAT 90.6m / Invested Capital 739.7m)
WACC = 8.07% (E(2.61b)/V(2.89b) * Re(8.83%) + D(278.3m)/V(2.89b) * Rd(1.23%) * (1-Tc(0.27)))
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.15%
[DCF Debug] Terminal Value 76.41% ; FCFF base≈84.7m ; Y1≈77.3m ; Y5≈68.1m
Fair Price DCF = 44.71 (EV 1.20b - Net Debt 270.1m = Equity 934.4m / Shares 20.9m; r=8.07% [WACC]; 5y FCF grow -10.93% → 2.90% )
EPS Correlation: 40.23 | EPS CAGR: 9.24% | SUE: -1.03 | # QB: 0
Revenue Correlation: 50.06 | Revenue CAGR: 2.44% | SUE: -0.80 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.40 | Chg30d=-0.005 | Revisions Net=+1 | Analysts=2
EPS next Year (2027-03-31): EPS=4.42 | Chg30d=+0.015 | Revisions Net=+1 | Growth EPS=+17.7% | Growth Revenue=+6.8%